Vitamin D: Activities for bone health

The Physiological Basis of Metabolic Bone Disease

Volumn , Issue , 2014, Pages 167-186

  Morris, Howard A ^a   Anderson, Paul H ^a   Nordin, B E Christopher ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Royal Adelaide Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938818617     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Mellanby E. 1919. An experimental investigation on rickets. Lancet 193: 407-412.
2. Ross AC et al. 2010. Committee to review dietary reference intakes for vitamin D and calcium. Institute of Medicine.
3. Holick MF et al. 2012. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metabol 97: 1153-1158.
4. DeLuca HF and Schnoes HK. 1976. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem 45: 631-666.
5. Morris HA and Anderson PH. 2010. Autocrine and paracrine actions of vitamin D. Clin Biochem Rev 31: 129-138.
6. Bischoff-Ferrari HA. 2012. Vitamin D: why does it matter? Defining vitamin D deficiency and its prevalence. Scand J Clin Lab Invest Suppl 243: 3-6.
7. Hendrix I et al. 2005. Response of the 5'-flanking region of the human 25-hydroxyvitamin D 1α-hydroxylase gene to physiological stimuli using a transgenic mouse model. J Mol Endocrinol 34: 237-245.
8. 2D3 levels. Bone 36: 654-662.
9. Malloy PJ et al. 2011. Hereditary 1,25-dihydroxyvitamin D-resistant rickets. in Vitamin D, Feldman, D et al., Eds. Academic Press: San Diego, pp. 1197-1232.
10. Brooks MH et al. 1978. Vitamin-D-dependent rickets type II: resistance of target organs to 1,25-dihydroxyvitamin D. New Engl J Med 298: 996-999.
11. Marx SJ et al. 1978. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metabol 47: 1303-1310.
12. Malloy PJ et al. 1999. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 20: 156-188.
13. Stumpf WE et al. 1979. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 206: 1188-1190.
14. Li YC et al. 1997. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94: 9831-9835.
15. Yoshizawa T et al. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16: 391-396.
16. Erben RG et al. 2002. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 16: 1524-1537.
17. Li YC et al. 1998. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139: 4391-4396.
18. Amling M et al. 1999. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140: 4982-4987.
19. Panda DK et al. 2004. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 279: 16754-16766.
20. Fraser D et al. 1973. Pathogenesis of hereditary vitamin-D-dependent rickets: an inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D. New Engl J Med 289: 817-822.
21. Glorieux FH et al. 2011. Pseudo-vitamin D deficiency. In Vitamin D, Feldman D et al., Eds. Academic Press: San Diego, pp. 1187-1195.
22. Fu GK et al. 1997. Cloning of human 25-hydroxyvitamin D-1 α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 11: 1961-1970.
23. Wang JT et al. 1998. Genetics of vitamin D 1α-hydroxylase deficiency in 17 families. Am J Hum Genet 63: 1694-1702.
24. Dardenne O et al. 2001. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(α)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 142: 3135-3141.
25. Need AG et al. 2008. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 23: 1859-1863.
26. Anderson PH et al. 2008. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res 23: 1789-1797.
27. Baker MR et al. 1979. Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br Med J 1: 589.
28. Morris HA et al. 1984. Vitamin D and femoral neck fractures in elderly South Australian women. Med J Austral 140: 519-521.
29. Lai JKC et al. 2010. Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies. BMC Publ Health 10.
30. Lidor C et al. 1993. Decrease in bone levels of 1,25-dihydroxyvitamin D in women with subcapital fracture of the femur. Calcif Tiss Intl 52: 146-148.
31. Ray D et al. 2009. Predisposition to vitamin D deficiency osteomalacia and rickets in females is linked to their 25(OH)D and calcium intake rather than vitamin D receptor gene polymorphism. Clin Endocrinol (Oxf) 71: 334-340.
32. Chapuy MC et al. 1992. Vitamin D3 and calcium to prevent hip fractures in the elderly women. New Engl J Med 327: 1637-1642.
33. Bischoff-Ferrari HA et al. 2012. A pooled analysis of vitamin D dose requirements for fracture prevention. New Engl J Med 367: 40-49.
34. Prentice RL et al. 2013. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporosis Intl 24: 567-580.
35. Avenell A et al. 2009. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev CD000227.
36. Nordin BE et al. 2004. Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures. Osteoporosis Intl 15: 27-31.
37. Need AG et al. 1997. The response to calcitriol therapy in postmenopausal osteoporotic women is a function of initial calcium absorptive status. Calcif Tiss Intl 61: 6-9.
38. Aaron JE et al. 1974. Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet 1: 229-233.
39. Wicks M et al. 1982. Absence of metabolic bone disease in the proximal femur in patients with fracture of the femoral neck. J Bone Joint Surg Br 64: 319-322.
40. Arnala I et al. 1997. Analysis of 245 consecutive hip fracture patients with special reference to bone metabolism. Ann Chir Gynaecol 86: 343-347.
41. Bell KL et al. 1999. Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck. Osteoporosis Intl 10: 248-257.
42. Omdahl JL et al. 2002. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 22: 139-166.
43. Cheng JB et al. 2004. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 101: 7711-7715.
44. Cheng JB et al. 2003. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase. J Biol Chem 278: 38084-38093.
45. Bieche I et al. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genom 17: 731-742.
46. Bikle DD et al. 1986. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metabol 63: 954-949.
47. Fraser DR and Kodicek E. 1970. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 228: 764-766.
48. Salle BL et al. 2000. Perinatal metabolism of vitamin D. Am J Clin Nutr 71: 1317S-1324S.
49. Kallas M et al. 2010. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metabol 95: 3111-3117.
50. Anderson PH et al. 2008. Co-expression of CYP27B1 enzyme with the 1.5 kb CYP27B1 promoter-luciferase transgene in the mouse. Mol Cell Endocrinol 285: 1-9.
51. St-Arnaud R and Naja RP. 2011. Vitamin D metabolism, cartilage and bone fracture repair. Mol Cell Endocrinol 347: 48-54.
52. Murayama A et al. 1998. The promoter of the human 25-hydroxyvitamin D3 1α-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1α,25(OH)2D3. Biochem Biophys Res Commun 249: 11-16.
53. Gao XH et al. 2002. Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1α-hydroxylase gene promoter in kidney AOK-B50 cells: role of Sp1, Ets, and CCAAT box protein binding sites. Int J Biochem Cell Biol 34: 921-930.
54. Zhong Y et al. 2009. Calcitonin, a regulator of the 25-hydroxyvitamin D3 1α-hydroxylase gene. J Biol Chem 284: 11059-11069.
55. Masuda S et al. 2005. Altered pharmacokinetics of 1a, 25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1)-null mouse. Endocrinology 146: 825-834.
56. Kerry DM et al. 1996. Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) promoter. J Biol Chem 271: 29715-29721.
57. Kumar R et al. 2010. Systematic characterisation of the rat and human CYP24A1 promoter. Mol Cell Endocrinol 325: 46-53.
58. Dwivedi PP et al. 2002. Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450c24 (CYP24) promoter: specific functions for ERK1/ERK2 and ERK5. J Biol Chem M204561200.
59. Zierold C et al. 2003. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem 88: 234-237.
60. Gao XH et al. 2004. Calcitonin stimulates expression of the rat 25-hydroxyvitamin D3-24-hydroxylase (CYP24) promoter in HEK-293 cells expressing calcitonin receptor: identification of signaling pathways. J Mol Endocrinol 32: 87-98.
61. Haussler MR et al. 2008. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 66: S98-S112.
62. Engel KB and Yamamoto KR. 2011. The glucocorticoid receptor and the coregulator Brm selectively modulate each other’s occupancy and activity in a gene-specific manner. Mol Cell Biol 31: 3267-3276.
63. Boland RL. 2011. VDR activation of intracellular signaling pathways in skeletal muscle. Mol Cell Endocrinol 347: 11-16.
64. Khanal R and Nemere I. 2007. Membrane receptors for vitamin D metabolites. Crit Rev Eukaryot Gene Expr 17: 31-47.
65. Nemere I et al. 2004. Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells. Proc Natl Acad Sci USA 101: 7392-7397.
66. Bravo S et al. 2006. The classic receptor for 1α,25-dihydroxy vitamin D3 is required for non-genomic actions of 1α,25-dihydroxy vitamin D3 in osteosarcoma cells. J Cell Biochem 99: 995-1000.
67. Wali RK et al. 2003. Vitamin D receptor is not required for the rapid actions of 1,25-dihydroxyvitamin D3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts. J Cell Biochem 88: 794-801.
68. Bikle DD. 2012. Vitamin D and the skin: physiology and pathophysiology. Rev Endocr Metabol Disord 13: 3-19.
69. Mulholland DJ et al. 2005. Interaction of nuclear receptors with the Wnt/β-catenin/ Tcf signaling axis: Wnt you like to know? Endocr Rev 26: 898-915.
70. Rawadi G and Roman-Roman S. 2005. Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 9: 1063-1077.
71. Haussler MR et al. 2010. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the “Fountain of Youth” to mediate healthful aging. J Steroid Biochem Mol Biol 121: 88-97.
72. Shah S et al. 2006. The molecular basis of vitamin D receptor and β-catenin cross-regulation. Mol Cell 21: 799-809.
73. Malloy PJ et al. 2002. A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol Endocrinol 16: 2538-2546.
74. Anderson PH and Atkins GJ. 2008. The skeleton as an intracrine organ for vitamin D metabolism. Mol Aspects Med 29: 397-406.
75. Suda T et al. 1995. Modulation of osteoclast differentiation by local factors. Bone 17: 87S-91S.
76. Takeda S et al. 1999. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 140: 1005-1008.
77. Anderson PH et al. 2011. Target genes: bone proteins. In Vitamin D, Feldman D et al., Eds. Elsevier Academic Press: San Diego, pp. 711-720.
78. Kogawa M et al. 2010. The metabolism of 25(OH)-vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Ster Biochem Mol Biol 121: 277-280.
79. Kogawa M et al. 2010. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology 151: 4613-4625.
80. Kogawa M et al. 2013. Modulation of osteoclastic migration by metabolism of 25OH-vitamin D3. J Steroid Biochem Mol Biol 136: 59-61.
81. Owen TA et al. 1991. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 128: 1499-1504.
82. Atkins GJ et al. 2007. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 α,25-dihydroxyvitamin D3. Bone 40: 1517-1528.
83. Atkins GJ et al. 2003. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 18: 1088-1098.
84. Yang D et al. 2013. Differential effects of 1,25-dihydroxyvitamin D on mineralisation and differentiation in two different types of osteoblast-like cultures. J Steroid Biochem Mol Biol 136: 166-170.
85. Morris HA et al. 1991. Calcium absorption in normal and osteoporotic postmenopausal women. Calc Tiss Intl 49: 240-243.
86. 45Ca gavage in the rat. J Steroid Biochem Mol Biol 103: 517-520.
87. Cochran M et al. 2005. The effect of calcitriol on fasting urine calcium loss and renal tubular reabsorption of calcium in patients with mild renal failure: actions of a permissive hormone. Clin Nephrol 64: 98-102.
88. Armbrecht HJ et al. 1989. Expression of calbindin-D decreases with age in intestine and kidney. Endocrinology 125: 2950-2956.
89. DeLuca HF. 2004. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80: 1689S-1696S.
90. Yamamoto Y et al. 2013. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 154: 1008-1020.
91. Lieben L et al. 2012. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest 122: 1803-1815.
92. Gardiner EM et al. 2000. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 14: 1908-1916.
93. Baldock PA et al. 2006. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res 21: 1618-1626.
94. Anderson PH et al. 2011. Vitamin D metabolism within bone cells: effects on bone structure and strength. Mol Cell Endocr 347: 42-47.
95. Atkins GJ et al. 2007. Metabolism of vitamin D(3) in human osteoblasts: evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D(3). Bone 40: 1517-1528.
96. Hendrix I et al. 2004. Regulation of gene expression by the CYP27B1 promoter study of a transgenic mouse model. J Ster Biochem Mol Biol 89-90: 139-142.
97. Anderson PH et al. 2010. The effect of dietary calcium on 1,25(OH)2D3 synthesis and sparing of serum 25(OH)D3 levels. J Ster Biochem Mol Biol 121: 288-292.
98. Turner AG et al. 2011. Increased bone volume in the bone-specific CYP27B1 transgenic mouse. Osteoporosis Intl 22: S590-S591.
99. Anderson PH et al. 2011. Enhanced vitamin D synthesis in osteoblasts protects against age-related bone loss. J Bone Miner Res 26: S151.
100. Lafage-Proust MH et al. 2013. High bone turnover persisting after vitamin D repletion: beware of calcium deficiency. Osteoporosis Intl 24: 2359-2363.